Abstract
The discovery of the key negative regulator MDM2 (mouse double minute 2, also termed HDM2 for its human equivalent) provided a great opportunity to manipulate the levels of the tumor suppressor p53 in cancer cells. Activation of p53 in tumor cells by inhibiting the interaction of MDM2 with p53 has therefore been the focus of a large effort in drug discovery. The modulation of protein-protein interactions, however, has historically been very difficult to achieve owing to the large surface area of interaction. In this article, we review the recent accomplishments in this area and our quest for a clinically viable MDM2 inhibitor.
Keywords: mdm2, p53, small molecule inhibitor, peptidic inhibitor, protein-protein interaction
Current Topics in Medicinal Chemistry
Title: Small Molecule Inhibitors of p53/MDM2 Interaction
Volume: 5 Issue: 2
Author(s): Nader Fotouhi and Bradford Graves
Affiliation:
Keywords: mdm2, p53, small molecule inhibitor, peptidic inhibitor, protein-protein interaction
Abstract: The discovery of the key negative regulator MDM2 (mouse double minute 2, also termed HDM2 for its human equivalent) provided a great opportunity to manipulate the levels of the tumor suppressor p53 in cancer cells. Activation of p53 in tumor cells by inhibiting the interaction of MDM2 with p53 has therefore been the focus of a large effort in drug discovery. The modulation of protein-protein interactions, however, has historically been very difficult to achieve owing to the large surface area of interaction. In this article, we review the recent accomplishments in this area and our quest for a clinically viable MDM2 inhibitor.
Export Options
About this article
Cite this article as:
Fotouhi Nader and Graves Bradford, Small Molecule Inhibitors of p53/MDM2 Interaction, Current Topics in Medicinal Chemistry 2005; 5 (2) . https://dx.doi.org/10.2174/1568026053507705
DOI https://dx.doi.org/10.2174/1568026053507705 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Clinical Applications of Multi-functional Milk Proteins and Peptides in Cancer Management
Current Medicinal Chemistry Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography
Current Pharmaceutical Design Potential Drug Targets on the HIV-1 Envelope Glycoproteins, gp120 and gp41
Current Pharmaceutical Design Cardiac Toxicities of Antiangiogenic Therapies
Current Angiogenesis (Discontinued) Inhibition of Cdc42-Interacting Protein 4 (CIP4) Impairs Osteosarcoma Tumor Progression
Current Cancer Drug Targets Epidermal Growth Factor Receptor Targeting in Non-Small Cell Lung Cancer: Revisiting Different Strategies Against the Same Target
Current Drug Targets Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies
Current Pharmaceutical Design Cancer Kinases and its Novel Inhibitors: Past, Present and Future Challenges
Current Drug Targets Molecular Genetics and Targeted Therapy in Hepatocellular Carcinoma
Current Cancer Drug Targets Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology:Theory, Data Acquisition,Analysis, and Examples
Current Medical Imaging To Enhance or to Inhibit Integrin Function in Angiogenesis, that is the Question
Current Angiogenesis (Discontinued) A Link Between Chemical Structure and Biological Activity in Triterpenoids
Recent Patents on Anti-Cancer Drug Discovery Human- and Virus-Encoded microRNAs as Potential Targets of Antiviral Therapy
Mini-Reviews in Medicinal Chemistry Inverse Regulation of MMP-9 and MMP-2 in Long-Term Follow-up After Acute Coronary Syndrome: Lack of Correlation with Platelet and Endothelial Cell Activation Markers
Vascular Disease Prevention (Discontinued) Emerging Strategies to Strengthen the Anti-Tumour Activity of Type I Interferons: Overcoming Survival Pathways
Current Cancer Drug Targets Withdrawal Notice: Recent Developments in Anti-Cancer Activity of Compounds Containing the Thioether Group
Anti-Cancer Agents in Medicinal Chemistry The Role of Shcbp1 in Signaling and Disease
Current Cancer Drug Targets Anabolic Factors in Degenerative Joint Disease
Current Drug Targets Virally Encoded G Protein-Coupled Receptors: Targets for Potentially Innovative Anti-Viral Drug Development
Current Drug Targets Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy
Current Gene Therapy